First, we complete the solid-state circuit breaker prototypes related for our first design win 3 months ahead ... and you're using 250 amp or 300 amp devices rather than 200 amp devices, you ...

FRANKFURT, May 26 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious ...

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results ... far surpassing placebo (3.2%). This efficacy ...

The Company expects to submit the New Drug Application for Xulane Lo in the second half of 2025. A low dose combination hormonal patch was found to be effective for pregnancy prevention based on ...

The new phase of development would bring more than 200 new housing options to the city ... Townhomes, which would be spread across the three blocks — dubbed one, six and 19 — would be three ...

But with promising early results from a phase 3 study in certain patients, the checkpoint inhibitor may have found its place. At a pre-specified interim analysis of Merck’s phase 3 Keynote-B96 ...

Residents of J.P. Nagar have raised serious concerns about the proposed double-decker flyover under Namma Metro Phase 3, warning that its alignment could worsen traffic congestion near the already ...

A breach below this could drag the index towards 23,500, which coincides with the 200 DEMA. A bearish engulfing pattern has emerged on the weekly chart, signalling further downside unless NIFTY ...

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem ...

Southwest Florida Crime Stoppers is seeking information to identify three women wanted for stealing from an Ulta Beauty store. According to Crime Stoppers, the theft occurred on Saturday ...

The objective response rate for LM was 51.6%, including a 15.6% complete response, and the disease control rate was 81.3% by BICR in the LM efficacy evaluable ... supporting its effective CNS ...

The results of the phase 3 BENEGENE-2 study demonstrated superiority with a mean ABR for all bleeds of 1.3 for the 12 months from week 12 to month 15 compared to an ABR of 4.43 during the lead-in ...